ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for default Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.
Journey Medical Corporation

Journey Medical Corporation (DERM)

5.18
-0.29
(-5.30%)
Closed June 22 4:00PM
5.18
0.00
(0.00%)
After Hours: 4:02PM

Real-time discussions and trading ideas: Trade with confidence with our powerful platform.

Key stats and details

Current Price
5.18
Bid
5.10
Ask
6.04
Volume
121,303
5.18 Day's Range 5.59
1.52 52 Week Range 8.11
Market Cap
Previous Close
5.47
Open
5.36
Last Trade Time
Financial Volume
$ 637,959
VWAP
5.2592
Average Volume (3m)
119,963
Shares Outstanding
20,012,896
Dividend Yield
-
PE Ratio
-26.91
Earnings Per Share (EPS)
-0.19
Revenue
79.18M
Net Profit
-3.85M

About Journey Medical Corporation

Journey Medical Corp is focused on identifying, acquiring, developing and strategically commercializing innovative, differentiated dermatology products through its efficient sales and marketing model. Journey Medical Corp is focused on identifying, acquiring, developing and strategically commercializing innovative, differentiated dermatology products through its efficient sales and marketing model.

Sector
Pharmaceutical Preparations
Industry
Pharmaceutical Preparations
Headquarters
Dover, Delaware, USA
Founded
1970
Journey Medical Corporation is listed in the Pharmaceutical Preparations sector of the NASDAQ with ticker DERM. The last closing price for Journey Medical was $5.47. Over the last year, Journey Medical shares have traded in a share price range of $ 1.52 to $ 8.11.

Journey Medical currently has 20,012,896 shares outstanding. The market capitalization of Journey Medical is $103.67 million. Journey Medical has a price to earnings ratio (PE ratio) of -26.91.

DERM Latest News

Journey Medical Corporation to Participate in the Alliance Global Partners’ (A.G.P.) Virtual Healthcare Company Showcase

SCOTTSDALE, Ariz., May 15, 2024 (GLOBE NEWSWIRE) -- Journey Medical Corporation (“Journey Medical” or “the Company”) (Nasdaq: DERM), a commercial-stage pharmaceutical company that primarily...

Journey Medical Corporation Reports First Quarter 2024 Financial Results and Recent Corporate Highlights

New Drug Application for DFD-29 to treat rosacea accepted for U.S. FDA review; PDUFA goal date of November 4, 2024 Total revenues for the first quarter ended March 31, 2024 were $13.0 million, a...

Journey Medical Corporation to Announce First Quarter 2024 Financial Results on May 13, 2024

SCOTTSDALE, Ariz., May 07, 2024 (GLOBE NEWSWIRE) -- Journey Medical Corporation (“Journey Medical” or the “Company”) (Nasdaq: DERM), a commercial-stage pharmaceutical company that focuses on the...

Journey Medical Corporation Appoints Joseph Benesch as Chief Financial Officer

SCOTTSDALE, Ariz., May 01, 2024 (GLOBE NEWSWIRE) -- Journey Medical Corporation (“Journey Medical” or “the Company”) (Nasdaq: DERM), a commercial-stage pharmaceutical company that primarily...

Journey Medical Corporation to Present at the Planet MicroCap Showcase: Vegas 2024

SCOTTSDALE, Ariz., April 25, 2024 (GLOBE NEWSWIRE) -- Journey Medical Corporation (“Journey Medical” or “the Company”) (Nasdaq: DERM), a commercial-stage pharmaceutical company that primarily...

Journey Medical Corporation Reports Full-Year 2023 Financial Results and Recent Corporate Highlights

Company generated total revenues of $79.2 million for the full year ended December 31, 2023, a 7% increase from the $73.7 million reported in 2022 Achieved $15.6 million in operating cost savings...

PeriodChangeChange %OpenHighLowAvg. Daily VolVWAP
1-0.19-3.538175046555.375.995.18733595.48938368CS
41.5843.88888888893.66.153.46011229504.94011622CS
121.6345.91549295773.556.153.21199634.19416611CS
26-2.45-32.11009174317.638.12.851698194.66412747CS
523.17157.7114427862.018.111.521720774.33862298CS
156-3.52-40.45977011498.710.21.02976884.33565069CS
260-4.6-47.03476482629.7825.991.0237510611.26535914CS

Market Movers

View all
  • Most Active
  • % Gainers
  • % Losers
SymbolPriceVol.
AREBAmerican Rebel Holdings Inc
$ 0.76
(152.49%)
371.46M
SHCRSharecare Inc
$ 1.365
(76.27%)
56.33M
NXLNexalin Technologies Inc
$ 1.7499
(59.08%)
57.58M
FUFUBitFuFu Inc
$ 6.1209
(56.95%)
2.5M
SPECSpectaire Holdings Inc
$ 0.50
(47.06%)
65.27M
FLFVFeutune Light Acquisition Corporation
$ 2.5502
(-69.75%)
862.38k
FLFVUFeutune Light Acquisition Corporation
$ 2.75
(-66.83%)
16.5k
RWODRedwoods Acquisition Corporation
$ 2.34
(-60.34%)
155.96k
KAVLKaival Brands Innovations Group Inc
$ 1.23
(-57.14%)
4.92M
RWODURedwoods Acquisition Corporation
$ 3.24
(-56.28%)
1.47k
NVDANVIDIA Corporation
$ 126.57
(-3.22%)
658.13M
AREBAmerican Rebel Holdings Inc
$ 0.76
(152.49%)
371.46M
SIRISirius XM Holdings Inc
$ 2.94
(1.38%)
330.66M
AAPLApple Inc
$ 207.49
(-1.04%)
246.38M
NKLANikola Corporation
$ 0.3466
(5.16%)
193.36M

DERM Discussion

View Posts
Monksdream Monksdream 2 months ago
DERM under $4

👍️0
Monksdream Monksdream 3 months ago
DERM under $4
👍️0
Awl416 Awl416 3 months ago
Solid day
👍️0
MiamiGent MiamiGent 12 months ago
DERM having a good morning:

$1.9299 +0.3399 (+21.38%)

https://stockcharts.com/h-sc/ui?s=DERM

BRIEF-Journey Medical Corporation Expects Topline Results FromPhase 3 Clinical Trials (MVOR-1 and MVOR-2) Evaluating DFD-29 For The Treatment Of Papulopustular Rosacea To Be Announced Week Of July 10
REUTERS 8:12 AM ET Jul-03-2023
July 3 (Reuters) - Journey Medical Corp (DERM.NaE):

* JOURNEY MEDICAL CORPORATION EXPECTS TOPLINE RESULTS FROM THE PHASE 3 CLINICAL TRIALS (MVOR-1 AND MVOR-2) EVALUATING DFD-29 (MINOCYCLINE HYDROCHLORIDE MODIFIED RELEASE CAPSULES, 40 MG) FOR THE TREATMENT OF PAPULOPUSTULAR ROSACEA TO BE ANNOUNCED WEEK OF JULY 10, 2023
👍️0
Covid19freak Covid19freak 1 year ago
$1.65 -Phase 3 results within days if positive this low floater could double or triple quickly

company has many marketed drugs and trading at cash ...DFD-29 will be the game changer for the company if successful in phase 3 , it has best in class potential in rosacea and the treatment could reach $100+ million in annual sales .

Achieved “Last Patient Out” milestone in Phase 3 clinical program evaluating DFD-29 in May 2023
Topline data are expected in June 2023 for Phase 3 clinical program evaluating DFD-29
👍️0
The Night Stalker The Night Stalker 1 year ago
nice pump
👍️0
bUrRpPPP! bUrRpPPP! 5 years ago
QBREXZA sales are a joke due to nasty side effects....patients not refilling...just not worth it...link for reviews

https://www.webmd.com/drugs/drugreview-175967-qbrexza-towelette.aspx
👍️0
bUrRpPPP! bUrRpPPP! 5 years ago
Derm...details of Roche deal is just horrible...link

https://www.fiercebiotech.com/biotech/roche-part-sale-mixed-bag-lebrikizumab-to-dermira
👍️0
bUrRpPPP! bUrRpPPP! 5 years ago
California dermatology biotech Dermira will take on exclusive worldwide rights to IL-13 monoclonal antibody lebrikizumab from Roche, although the Big Pharma holds on to its rights for the med in certain indications.

The complex deal could be worth more than $1 billion in biobucks: Drilling down into the numbers, Dermira will make a first payment of $80 million to Roche, with future payments worth $55 million coming next year.

But that’s not all, as Dermira will also need to cough up extra payments if the med hits certain milestones, made up of $40 million when Dermira’s first phase 3 clinical study is started, and up to $210 million when it hits regulatory and first commercial sale milestones “in certain territories."
Webinar
How ICON, Lotus, and Bioforum are Improving Study Efficiency with a Modern EDC
CROs are often at the forefront of adopting new technologies to make clinical trials more efficient. Hear how ICON, Lotus Clinical Research, and Bioforum are speeding database builds and automating reporting tasks for data management.
Register Now

And then there’s the big number: $1.025 billion, based on the “achievement of certain thresholds for net sales of lebrikizumab,” in indications other than interstitial lung disease, which Roche will be hanging on to.

And should it gain approval, Dermira will also be making royalty payments “representing percentages of net sales that range from the high single-digits to the high teens.”

This comes after a mixed bag of data for the med, as last February, Roche suffered a setback when it posted one win and one loss for identical phase 3 studies for lebrikizumab in asthma patients.

The side-by-side studies were designed to give Roche a solid foundation of data for the approval and marketing of the anti-inflammatory drug for a clearly defined patient population.

But while Lavolta I hit its primary endpoint on significantly cutting the rate of asthma exacerbations among patients selected on two key biomarkers for airway inflammation, levels of serum periostin or blood eosinophils, Lavolta II missed the exact same measure of efficacy.

Ironically, Dermira, which got off a $125 million IPO in 2014 and now has a market cap north of $1 billion, has seen a similar situation with its experimental sweat drug DRM04, which last summer passed one Phase 3 test, but narrowly missed its target on a second late-stage trial, although analysts believed this would still be good enough to gain an FDA approval.
👍️0
bUrRpPPP! bUrRpPPP! 5 years ago
Derm design phase 2 study is a joke...patients were required to use TCS twice daily ...OBJECTIVE:

We investigated the efficacy and safety of lebrikizumab, an IL-13 monoclonal antibody, as an add-on to topical corticosteroid (TCS) treatment

https://www.ncbi.nlm.nih.gov/pubmed/29353026

METHODS:

A randomized, placebo-controlled, double-blind, phase 2 study. Adults with moderate-to-severe AD were required to use TCS twice daily and then randomized (1:1:1:1) to lebrikizumab 125 mg single dose, lebrikizumab 250 mg single dose, lebrikizumab 125 mg every 4 weeks for 12 weeks, or placebo every 4 weeks for 12 weeks, after a 2-week TCS run-in. The primary endpoint was percentage of patients achieving Eczema Area and Severity Index (EASI)-50 at week 12.
RESULTS:

In total, 209 patients received the study drug. At week 12, significantly more patients achieved EASI-50 with lebrikizumab 125 mg every 4 weeks (82.4%; P = .026) than placebo every 4 weeks (62.3%); [/]patients receiving a single dose of lebrikizumab showed no statistically significant improvements in EASI-50 compared with placebo. Adverse events were similar between groups (66.7% all lebrikizumab vs 66.0% placebo) and mostly mild or moderate.
LIMITATIONS:

Protocol-mandated twice daily TCS treatment limits our understanding of the efficacy of lebrikizumab as a monotherapy. The short study duration did not enable long-term efficacy or safety evaluations.
CONCLUSION:

When combined with TCS, lebrikizumab 125 mg taken every 4 weeks led to a significant improvement and was well tolerated in patients with moderate-to-severe AD.
👍️0
ClayTrader ClayTrader 5 years ago
* * $DERM Video Chart 11-08-19 * *

Link to Video - click here to watch the technical chart video

👍️0
CA CHASE CA CHASE 5 years ago
$DERM $9... $8.50.. HOW ABOUT $8 THEN $7.50

PHARMA TRASH $ANAB $DERM
👍️0
CA CHASE CA CHASE 5 years ago
$DERM ANOTHER PHARMA SPIKE ON HYPE / SHORT THIS POS, $9 TO $8.55

"YOU'RE THE NEXT CONTESTANT ON THE PRICE IS TOO HIGH!"

F-PHARMA
👍️0
CA CHASE CA CHASE 5 years ago
$DERM ALRIGHTY.. LET'S SHORT THIS POS :) $9... LOL TIMBERRRRRRRRRRRRRR

F-PHARMA
👍️0
ClayTrader ClayTrader 5 years ago
* * $DERM Video Chart 10-18-2019 * *

Link to Video - click here to watch the technical chart video

👍️0
PennyStock Alert PennyStock Alert 5 years ago
we got comps
👍️0
bUrRpPPP! bUrRpPPP! 5 years ago
Analyst Irina Koffler also lowered her price target for the Menlo Park, California-based company to $14 from $17 a share. She said in a note to investors that she expects the Spanish pharmaceutical company Almirall to exercise its European rights to lebrikizumab, a treatment of moderate-to-severe atopic dermatitis.
Koffler said she attributes a 40% share selloff of the company's stock since April to financing uncertainty and the "lackluster" performance of the prescription anticholinergi Qbrexza.

"We believe Dermira could be strategically attractive to dermatology-focused companies," Koffler wrote. "We believe there could be significant cost synergies associated with cutting Qbrexza SG&A (Selling, General and Administrative Expenses)."

Koffler said that "the chief risk to our thesis is that Almirall walks away from EU rights."

"If Almirall abandons the deal, it may discourage other strategic interest in lebrikizumab as well," she wrote. "In this case, it's possible that Dermira would need to develop lebrikizumab on its own and pursue multiple financing rounds in the future against a limited catalyst calendar over the next three years while we await lebrikizumab approval and launch. Based on the pending Dermavant IPO focused on a Phase III psoriasis biologic, we believe the category is still attractive to investors and strategics and we view this scenario as unlikely."
👍️0
NSX NSX 5 years ago
Gave back significant gain after the last news. Healthcare sector fears holding this one back.

NSX sell rating for now, but keep an eye on this one and the chart.
👍️0
BottomBounce BottomBounce 5 years ago
Dermira, Inc. $DERM https://www.prnewswire.com/news-releases/thinking-about-buying-stock-in-aurora-cannabis-inc-dermira-inc-nio-inc-soleno-therapeutics-inc-or-worldpay-inc-300813883.html
👍️0
BottomBounce BottomBounce 5 years ago
$DERM https://www.barchart.com/story/news/load-more-stories/1125662/thinking-about-buying-stock-in-aurora-cannabis-inc-dermira-inc-nio-inc-soleno-therapeutics-inc-or-worldpay-inc
👍️0
bUrRpPPP! bUrRpPPP! 5 years ago
Hi Clay..Maybe we can get an updated DERM chart after the close? thanks!
👍️0
NSX NSX 5 years ago
Excellent Clay. Thanks
👍️0
BottomBounce BottomBounce 5 years ago
$DERM Thinking about buying stock in Aurora Cannabis Inc., Dermira Inc., Nio Inc., Soleno Therapeutics Inc., or Worldpay, Inc.?
https://www.prnewswire.com/news-releases/thinking-about-buying-stock-in-aurora-cannabis-inc-dermira-inc-nio-inc-soleno-therapeutics-inc-or-worldpay-inc-300813883.html
👍️0
ClayTrader ClayTrader 5 years ago
* * $DERM Video Chart 03-18-2019 * *

Link to Video - click here to watch the technical chart video

👍️0
NSX NSX 5 years ago
$14.04 is break point
👍️0
NSX NSX 5 years ago
Did you see the conversion line on the 10 minutes shoot straight up over the base line....dear lord

next, look at the 30 minutes. If the same happens then load up for a quick gain

NSX
👍️0
NSX NSX 5 years ago
Look for the conversion line to cross up and over the base line on the 10 minute chart and in 20 minutes, the same on the 30 minute as confirmation of another 50% rise!

otherwise she drifts back to 12.23!!

watch closely and make money
👍️0
NSX NSX 5 years ago
I see a bullish rise even yet.....

the gap will fill at some point, but not today
👍️0
TheFinalCD TheFinalCD 5 years ago
11.15 DIP FROM 14.98

DERM
👍️0
TheFinalCD TheFinalCD 5 years ago
8-K OUT https://ih.advfn.com/stock-market/NASDAQ/dermira-inc-DERM/stock-news/79491262/current-report-filing-8-k

some big buying around $12 area

I sold 12.94





👍️0
TheFinalCD TheFinalCD 5 years ago
Dermira Announces Positive Topline Results from Phase 2b Study of Lebrikizumab in Patients with Atopic Dermatitis

https://www.globenewswire.com/news-release/2019/03/18/1756186/0/en/Dermira-Announces-Positive-Topline-Results-from-Phase-2b-Study-of-Lebrikizumab-in-Patients-with-Atopic-Dermatitis.html
👍️0
Opti Mist Opti Mist 6 years ago
Very glad I sold yesterday at 10.26 for a modest gain. I will take a modest gain over a significant loss any day.

Opti
👍️0
Grandmasters Grandmasters 6 years ago
DERM 30% Returns from $10.00

Patience folks.
👍️0
Opti Mist Opti Mist 6 years ago
this was not a good week. Down 3-5% daily.

troubling.

Opti
👍️0
Opti Mist Opti Mist 6 years ago
Time for DERM to climb back above $10

Opti
👍️0
crudeoil24 crudeoil24 6 years ago
FDA > APPROVAL !!!!!
👍️0
crudeoil24 crudeoil24 6 years ago
Dermira's Qbrexza For Treatment Of Excessive Underarm Sweating Gets FDA Approval -- MarketWatch
7:10 am ET June 29, 2018 (MarketWatch)
Share
Print
Dermira Inc. (DERM) said Friday its Qbrexza cloth for topical treatment of primary axillary hyperhidrosis, or excessive underarm sweating, was approved by the Food and Drug Administration. Qbrexza is indicated for adult and pediatric patients nine years of age and older. The biopharmaceutical company said the cause of primary axillary hyperhidrosis is unknown, but affects nearly 10 million people in the U.S. The company expects Qbrexza to be available nationwide in pharmacies beginning in October 2018. The stock is currently halted for news until 7:30 a.m. ET. It has tumbled 68% year to date through Thursday, while the iShares Nasdaq Biotechnology ETF (IBB) has gained 1.1% and the S&P 500 has edged up 1.6%.

-Tomi Kilgore

For more from MarketWatch: http://www.marketwatch.com/newsviewer

(END) Dow Jones Newswires

June 29, 2018 07:10 ET (11:10 GMT)

Copyright (c) 2018 Dow Jones & Company, Inc.
👍️0
seppi08162 seppi08162 6 years ago
What is going on this morning....
👍️0
Ijohnrob Ijohnrob 6 years ago
Good luck, hopefully we start moving up soon
👍️0
girlfriend girlfriend 6 years ago
Added a few more DERM at 7.9
👍️0
girlfriend girlfriend 6 years ago
Added a few at 8.40 and 8.48 on selloff Friday. Good luck to us!
👍️0
Ijohnrob Ijohnrob 6 years ago
I think $12 is reasonable in short term. I’ll probably cash out soon, even though I think long term may go above $20 — good one to keep an eye on. Good luck
👍️0
girlfriend girlfriend 6 years ago
I am here too but sold half from mid 8’s yesterday. Hoping for 12 target to unload rest....good luck
👍️0
Ijohnrob Ijohnrob 6 years ago
Am I the only one here — got in 8.75 — this is going to continue up!!
👍️0
Ijohnrob Ijohnrob 6 years ago
BS
👍️0
girlfriend girlfriend 6 years ago
Link please....DERM not acting like he did so far

<Carl Icahn took stake today>


Thank you
👍️0
Biggeoff Biggeoff 6 years ago
Carl Icahn took stake today
👍️0
Juschilln Juschilln 6 years ago
You think?
👍️0
conix conix 6 years ago
This cat may be dead.
👍️0
$treet $inatra $treet $inatra 6 years ago
Huge Drop!! Monster GAP DOWN!!
👍️0

Your Recent History

Delayed Upgrade Clock